Sanofi expanded its venture capital arm with a $625 million cash infusion to invest in biotech startups, reflecting a focus on advancing scientific innovation amid tight capital markets. Meanwhile, Eli Lilly announced a $6.5 billion investment to build a Texas facility dedicated to production of its oral GLP-1 obesity drug. These strategic moves underscore major pharmaceutical companies’ commitments to strengthen their biopharma infrastructure and pipeline capabilities in metabolic disease and beyond.